Your Top 100 most-cited badge
A badge for your website, a sentence for your CV, and a permanent page where anyone can check the rank.
The article
VP10-2021: Cabozantinib (C) plus atezolizumab (A) versus sorafenib (S) as first-line systemic treatment for advanced hepatocellular carcinoma (aHCC): Results from the randomized phase III COSMIC-312 trial
Robin Kate Kelley, Thomas C. C. Yau, Ann‐Lii Cheng, Ahmed Omar Kaseb, Shukui Qin, Andrew Xiuxuan Zhu and 13 more
- Rank
- 82 of 3,031
- Percentile
- top 2.8%
- Where
- Annals of Oncology, 2021
- Citations
- 75
From the 2021 list, OpenAlex counts as of 2026-10-29.
Prefer not to be listed? The same link lets you withhold your name on every list; the article stays, your name does not. Questions: team@avidnote.com.